Found 11 results
Author Title [ Type(Asc)] Year
Filters: Author is Bailer, RT  [Clear All Filters]
Journal Article
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 303 St, “A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial”, J Infect Dis, vol. 203, pp. 1396-1404, 2011.
J. E. Martin, Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B., Andrews, C., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 301 St, “A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial”, Vaccine, vol. 26, pp. 6338-6343, 2008.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., Graham, B. S., and Team, T. V. R. C. 201/20, “Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals”, Vaccine, vol. 25, pp. 1513-1525, 2007.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 310 St, “Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect”, J Infect Dis, vol. 208, pp. 418-422, 2013.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L., Bailer, R. T., Roederer, M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 011 St, “Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (i.m.), Subcutaneous (s.c.) and Intradermal (i.d.) Administration (VRC 011)”, PLoS ONE, vol. 9, p. e91366, 2014.
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 007 St, “Phase I Clinical Evaluation of a Six-Plasmid Multiclade HIV-1 DNA Candidate Vaccine”, Vaccine, vol. 25, pp. 4085-4092, 2007.
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B., Gall, J., King, C., Andrews, C., Sheets, R., Gomez, P., Mascola, J., Nabel, G., Graham, B., and Team, T. Vaccine Re, “Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector”, J Infect Dis, vol. 194, pp. 1638-1649, 2006.
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., ,, Ledgerwood, J. E., Graham, B. S., and Team, T. V. R. C. 015 St, “Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses Despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial”, PLoS One, vol. 9, p. e106240, 2014.
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., ,, Bailer, R. T., Roederer, M., Koup, R. A., Nabel, G. J., and Team, T. V. R. C. 008 St, “DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-cell Responses After rAd5 Boost in a Randomized Clinical Trial”, PLoS One, vol. 8, p. e59340, 2013.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., Graham, B. S., and Team, andThe V. R. C. 70, “DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial”, PLoS One, vol. 10, p. e0125914, 2015.
Conference Paper
J. E. Ledgerwood, Yamschikov, G., Enama, M. E., Sarwar, U. N., Bailer, R. T., Larkin, B., Bellamy, A. R., Anderson, E. L., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P., and Graham, B., “VRC 702: A Multicenter Phase 1 Study of Seasonal Influenza DNA Vaccine Prime Followed by the Trivalent Inactivated Vaccine (TIV) Compared to TIV-TIV in Children and Adolescents Ages 6-17 Years”, in 2014 Annual Conference on Vaccine Research, Bethesda, MD, 2014.